Abstract:9066 Background: Large-cell neuroendocrine carcinoma (LCNEC) is a rare tumor with a poor prognosis and limited treatment options. The efficacy of first-line therapies for LCNEC has not yet been established. This study evaluated the efficacy and safety of the combination of PD-1/PD-L1 inhibitor and platinum-based chemotherapy in treatment-naïve patients with advanced LCNEC. Methods: We retrospectively analyzed patients with advanced LCNEC who were treated with a PD-1/PD-L1 inhibitor plus platinum-based chemotherapy (PD-1/PD-L1 inhibitor group) or with platinum-based chemotherapy alone (chemotherapy group) based on data obtained from electronic databases of three participating cancer centers from January 2015 to August 2022. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) were evaluated for each group. Safety was assessed in all patients who received at least one dose of their assigned treatment. Results: Among the 75 enrolled patients, 25 were allocated to receive PD-1/PD-L1 inhibitor plus platinum-based chemotherapy and 50 were allocated to receive platinum-based chemotherapy alone (patients were matched 1:2 on baseline characteristics). The median PFS was 15.1 months (95% confidence interval [CI], 7.1–23.2) in the PD-1/PD-L1 inhibitor group and 5.3 months (95% CI, 4.4–6.2) in the chemotherapy group (hazard ratio [HR], 0.26; 95% CI, 0.113–0.428; p < 0.0001). The 12-month OS was 88.0% (95% CI, 67.7–96.9) in the PD-1/PD-L1 inhibitor group and 56.0% (95% CI, 41.4–69.7) in the chemotherapy group ( p = 0.0056). The ORRs in the two groups were 40% and 16%, respectively ( p = 0.022), and the DCRs were 96% and 70%, respectively ( p = 0.010). Regarding safety, the most common incidences of grade ≥ 3 adverse events involved neutropenia, leukopenia, anemia, and fatigue. There were no significant differences between the two groups. Immune-related adverse events (irAEs) in the PD-1/PD-L1 inhibitor group included cutaneous hemangiomas, hypothyroidism, anaphylaxis, and pneumonitis. Grade 3 or 4 irAEs were not observed. No new safety signals were noted. Conclusions: First-line PD-1/PD-L1 inhibitor plus platinum-based chemotherapy significantly improved PFS in patients with advanced LCNEC compared with platinum-based chemotherapy alone.

Irinotecan Plus Cisplatin Followed by Octreotide Long-Acting Release Maintenance Treatment in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma: IPO-NEC Study

A Phase II Study of Sequential Irinotecan Plus Cisplatin (IP) and Octretide LAR As First-Line Treatment of Metastatic or Inoperable Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC).

First-Line Irinotecan Combined with 5-Fluorouracil and Leucovorin for High-Grade Metastatic Gastrointestinal Neuroendocrine Carcinoma

Feasibility and Efficacy of Combined Cisplatin Plus Irinotecan Chemotherapy for Gastroenteropancreatic Neuroendocrine Carcinomas

Etoposide and Cisplatin Versus Irinotecan and Cisplatin As the First-Line Therapy for Patients with Advanced, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: A Randomized Phase 2 Study.

Advances in the treatment of gastroenteropancreatic poorly differentiated neuroendocrine carcinoma at our hospital.

Efficacy of first-line chemotherapy based on primary site of tumor versus etoposide-platinum in advanced gastroenteropancreatic neuroendocrine carcinoma

Sintilimab Plus Oxaliplatin/capecitabine (capeox) As Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric (g)/esophagogastric Junction (GEJ) Adenocarcinoma.

Long-term Survival of Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasm: Two Case Reports.

377O A Randomized Double-Blind Phase III Study of Niraparib Versus Placebo As Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Oxaliplatin Plus Irinotecan Vs Irinotecan As Second-Line Treatment in Pancreatic Cancer Patients: a Randomized-Controlled Open-Label Phase II Study

177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

Combined Chemotherapy with Lrinotecan and Cisplatin As A Second-line Regimen for Patients with Advanced Gastric Cancer

First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study

Irinotecan- Vs Oxaliplatin-Based Regimens for Neoadjuvant Chemotherapy in Colorectal Liver Metastasis Patients: A Retrospective Study.

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Preliminary Analysis of Folfiri Regimen with or Without Bevacizumab As Second-Line Systemic Therapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma.

A Phase Ii Study Of Irinotecan As Single Agent In The Third-Line Treatment Of Unresectable Or Metastatic Gastric Cancer.

Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study

Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of the lung.